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BACKGROUND: O
6-methylguanine-DNA methyltransferase (MGMT) expression in glioblastoma correlates with temozolomide
resistance. Dose-intense temozolomide schedules deplete MGMT activity in peripheral blood mononuclear cells; however, no
published data exist evaluating the effect of temozolomide schedules on intracranial tumour MGMT activity.
METHODS: Human glioblastoma cells (GBM43) with an unmethylated MGMT promoter were implanted intracranially in
immunodeficient rodents. Three weeks later, animals received temozolomide 200mgm
 2 for 5 days (schedule A, standard dose)
or 100mgm
 2 for 21 days (schedule B, dose intense).
RESULTS: Tumour MGMT activity was depleted by day 6 in both treatment groups compared with baseline. O
6-methylguanine-DNA
methyltransferase activity returned to baseline by day 22 in the schedule A group, but remained suppressed in the schedule B group.
By day 29, MGMT activity had returned to baseline in both groups. Mean tumour volume was significantly decreased compared with
untreated controls with either schedule (Po0.01), although neither schedule was superior (P¼0.60). Median survival was 64, 42, and
28 days for schedule A, schedule B, and no drug, respectively (Po0.001 A or B vs control, P¼NS A vs B).
CONCLUSIONS: Dose-intense temozolomide prolongs tumour MGMT activity depletion compared with standard dosing, however,
survival was not improved in this model.
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In 2005, Stupp et al published the results of a landmark trial
(EORTC 22981/26981, NCIC CE. 3) showing a significant survival
improvement in patients with newly diagnosed glioblastoma
treated with radiotherapy and temozolomide (Temodar,
SCH52365, NSC362856, Schering-Plough, Kennilworth, NJ, USA)
vs radiotherapy alone. Temozolomide is an oral alkylating agent
that exerts its cytotoxic effect through methylation of the O
6
position of guanine. The O
6-methylguanine lesion is recognised by
the DNA mismatch repair (MMR) pathway, and cytotoxicity is
thought to result from repeated failure of MMR to repair the
lesion, which results in DNA double-strand breaks and apoptosis
(Bignami et al, 2000; Roos et al, 2007). O
6-methylguanine-DNA
methyltransferase (MGMT) is the sole enzyme capable of repairing
the O
6-methylguanine adduct, and the level of MGMT in cells is
directly correlated with alkylating agent cytotoxicity (Dumenco
et al, 1989; Schold et al, 1989). In a correlative study using a subset
of tumour samples from EORTC 22981/26981 by Hegi et al (2005),
median survival was significantly improved in those patients
treated with temozolomide in whom tumour MGMT was
inactivated by hypermethylation of CpG islands in the promoter
region. Although epigenetic inactivation of MGMT is present
in approximately 40% of newly diagnosed glioblastoma, the
remaining tumours have normal or even elevated levels of MGMT
and are resistant to treatment with temozolomide (Esteller et al,
1999; Paz et al, 2004). Thus, depletion of MGMT activity in these
tumours should result in enhanced sensitivity to temozolomide.
One approach to inhibiting MGMT activity involves the delivery
of temozolomide using dose-intense schedules that generate
sufficiently large numbers of O
6-methylguanine adducts such that
total cellular MGMT is depleted. If the schedule could be delivered
in a manner such that the generation of O
6-methylguanine lesions
was to outstrip the rate of MGMT synthesis, cytotoxicity should be
enhanced. Early preclinical and clinical studies revealed temozo-
lomide to have significant schedule-dependent anti-tumour
activity, with more frequent dosing schedules producing greater
cytotoxicity than less frequent schedules (Stevens et al, 1987;
Newlands et al, 1997). Standard dose temozolomide, as delivered
for its original FDA-approved indication in the treatment of
recurrent high-grade glioma, is dosed at 150–200mgm
 2 for
5 days every 28 days (Yung et al, 1999, 2000). This dosing schedule
was also used after concurrent temozolomide and radiation in
EORTC 22981/26981. A number of studies have since been
undertaken to test the safety and efficacy of dose-intense schedules
of temozolomide in patients with newly diagnosed and recurrent
high-grade glioma. The most commonly used dose-intense
schedules treat patients with temozolomide at 150mgm
 2 given
7 days on, 7 days off, or 100mgm
 2 given 21 days on, 7 days off,
both of which deliver a dose intensity of approximately 2.1 relative
to the standard dose regimen (Wick et al, 2004, 2007; Athanassiou
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set al, 2005; Caroli et al, 2007; Chinot et al, 2007; Neyns et al, 2008).
Although control rates using dose-intense temozolomide regimens
seem to be improved compared with historical controls, Grade 3/4
lymphocytopenia rates ranging from 30 to 100% have been reported
(Brock et al, 1998; Wick and Weller, 2005; Neyns et al, 2008).
To test the hypothesis that dose-intense treatment schedules of
temozolomide might improve overall survival for patients with
newly diagnosed glioblastoma, the Radiation Therapy Oncology
Group (RTOG 0525) randomised over 1000 patients treated with
surgical resection and external beam radiation therapy (60Gy
in 30fx) with concurrent temozolomide (75mgm
 2 daily
during radiation) to adjuvant temozolomide on a (1) standard
(200mgm
 2 for 5 days every 28 days) or (2) dose-intense schedule
(100mgm
 2 for 21 days every 28 days). Enrollment has completed,
and preliminary results are anticipated shortly.
Overall, our understanding of the kinetics of MGMT activity
depletion by alkylating agents in normal tissues and tumour are
limited. In a seminal phase I study by Tolcher et al (2003), dose-
intense schedules of temozolomide were found to reliably deplete
MGMT activity in peripheral blood mononuclear cells (PBMCs).
To date, however, there are no studies evaluating the effect of
dose-intense temozolomide schedules on MGMT activity in brain
tumours. Therefore, we sought to characterise the effect of the
clinically relevant standard and dose-intense temozolomide arms
from RTOG 0525 on intracranial tumour MGMT activity and
survival using an orthotopic xenograft model.
MATERIALS AND METHODS
Glioblastoma model
GBM43 cells were generously provided by Jann Sarkaria
(Department of Radiation Oncology, Mayo Clinic). GBM43 was
originally derived from a 69-year-old man who underwent
resection of a left temporal glioblastoma, and has been maintained
as a part of a human GBM xenograft panel as previously described
(Giannini et al, 2005; Sarkaria et al, 2006). GBM43 cells have
been previously characterised as having an unmethylated
MGMT promoter, and express functional MGMT protein (Kitange
et al, 2009).
Orthotopic xenograft model
All experiments were performed on a protocol approved by the
Cleveland Clinic Institutional Animal Care and Use Committee
(IACUC no. 08517). Animals were fed a standard rodent diet, and
maintained in a pathogen-free environment. GBM43 cells were
grown in short-term cell culture (7–14 days) at 371C with 5% CO2
in DMEM supplemented with 10% fetal bovine serum, and 1%
antibiotic/antimycotic (Invitrogen, Carlsbad, CA, USA). Immedi-
ately before inoculation, cells were harvested by trypsinisation and
suspended in PBS to a concentration of 1 10
6 cellsml
–1. GBM43
cells were inoculated into the right basal ganglia of anaesthetised
athymic nude mice (nu/nu, Charles River, Wilmington, MA, USA)
or rats (RNu, Charles River) using a stereotactic frame (David Kopf
Instruments, Tujunga, CA, USA). Mice were inoculated with
3 10
6 GBM43 cells in a total volume of 3ml, and rats were
inoculated with 5 10
6 GBM43 cells in a total volume of 5ml.
Temozolomide dosing schedules
Animals treated with the standard dose schedule (schedule A)
received intraperitoneal temozolomide at a dose of 200mgm
 2
for 5 days, and those treated with the dose-intense schedule
(schedule B) received temozolomide at a dose of 100mgm
 2 for
21 days. Body surface area (BSA) dosing was converted to mgkg
–1
dosing using the BSA normalisation method (Reagan-Shaw et al,
2008). Using a Km factor of 3 for mice, schedule A was given at
66.6mgkg
 1 for 5 days and schedule B was given at 33.3mgkg
 1
for 21 days. Using a Km factor of 6 for rats, schedule A was given at
33.3mgkg
 1 for 5 days and schedule B was given at 16.7mgkg
 1
for 21 days. Reagent-grade temozolomide was obtained from
OChem, Inc. (Des Plaines, IL, USA), and dissolved in PBS with 10%
DMSO immediately before injection.
Effect of temozolomide dosing on tumour MGMT activity
Three weeks after inoculation with GBM43, animals were
randomised to treatment with temozolomide on schedule A or
schedule B. At serial time points after the initiation of treatment,
2–3 animals per treatment group were killed and intracranial
tumour was removed. Tumour was snap frozen in liquid nitrogen,
and stored at  801C for subsequent MGMT activity analysis.
Intracranial tumour was extracted from three animals on day 1 of
the experiment for assessment of pretreatment tumour MGMT
activity. In the rat cohort, intracranial tumour was extracted from
two randomly selected animals in each treatment group on days 3,
6, 10, 15, and 22 after the initiation of treatment. In the mouse
cohort, intracranial tumour was extracted from three randomly
selected animals in each treatment group on days 6, 22, and 29
after the initiation of treatment. MGMT activity in frozen tumour
samples was measured as removal of [
3H]methyl adduct from the
O
6 position of guanine in DNA by incubating tissue extracts with
excess [
3H]methyl-DNA substrate as previously described (Gerson
et al, 1986; Spiro et al, 1999). MGMT activity is reported as fmol
O
6mG per mg DNA.
Effect of temozolomide dosing on tumour volume
Three weeks after inoculation with GBM43, mice were randomised
to treatment with no drug, or temozolomide on schedule A or
schedule B. On day 0, five untreated control mice were killed and
the whole brain was removed. On day 22, all remaining mice were
killed and the whole brain was removed. Whole brains were fixed
in 10% paraformaldehyde for at least 3h, and then washed three
times for 10min in PBS. After fixation, they were immersed in 10%
sucrose in PBS overnight and then 20% sucrose in PBS until the
sample reached the bottom of the tube. They were then frozen in
OCT (Tissue-Tek – Sakura – OCT Compound, Sakura Finetek
USA, Inc., Torrance, CA, USA) and 10mm cryosections were made
(Leica CM3050 S cryostat, Leica Microsystems, GmbH, Wetzlar,
Germany) and mounted on glass slides.
Slides were stained with hematoxylin and eosin and mounted
using Cytoseal TM (Stephens Scientific, Wayne, NJ, USA)
mounting medium. A whole tissue section on a slide was imaged
with a Leica DM5000B microscope (Leica Microsystems) equipped
with a Prior Motorised Stage and Linearly Encoded Controller
(Prior Scientific, Inc., Rockland, MA, USA) and Retiga SRV Cooled
CCD camera with Liquid Crystal tunable RGB filter (QImaging,
Surrey, BC Canada). Through an automated ‘tiled-mosaic’ process,
this microscope allows the acquisition of an image of an entire
tissue sample with a 5  magnification. Tumours were measured
using ImagePro software (Version 6.1.0.346, Media Cybernetics,
Bethesda, MD, USA), and tumour volumes were calculated using a
modified ellipsoidal formula: 1/2(length   width
2) where length is
the greatest longitudinal diameter and width is the greatest
transverse diameter. The effect of temozolomide treatment on
tumour volume was evaluated using the two-tailed Students’ t-test.
Effect of temozolomide dosing on survival
Three weeks after inoculation with GBM43, 30 mice were
randomised to treatment with no drug (n¼10), schedule A
(n¼10), or schedule B (n¼10). Mice were examined daily, and
were killed if they developed abnormal behaviour, evidence of pain
or distress, or 420% weight loss. Survival was evaluated using the
Dose-intense vs standard dose temozolomide
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sKaplan–Meier method, and was calculated from the first day of
treatment. Survival between temozolomide treatment schedules
was compared using the log-rank test.
RESULTS
Effect of temozolomide dosing on tumour MGMT activity
RNu rats inoculated orthotopically with GBM43 tumour were
treated with temozolomide using a standard dose (schedule A,
200mgm
 2 for 5 days) or dose-intense (schedule B, 100mgm
 2
for 21 days) schedule. Mean MGMT activity from the extracted
brain tumours is plotted in Figure 1A, and tabulated in Table 1.
Three days after the initiation of treatment, both schedules
depleted tumour MGMT activity to o5% of pretreatment levels.
On day 6, MGMT activity in tumour remained suppressed in both
groups. By day 10 MGMT activity returned to 50% of pretreatment
levels in the Schedule A group, but remained at o25% of
pretreatment levels in the schedule B group. In the schedule A
group, tumour MGMT activity returned to pretreatment levels by
day 15, and remained elevated on day 22. In contrast, tumour
MGMT activity in the schedule B group remained suppressed to
30–40% of pretreatment levels on day 15 and 22. It is noteworthy
that while the dose-intense schedule effectively suppressed MGMT
activity during the course of treatment, activity seemed to rebound
somewhat during days 10–22 compared with the maximum
suppression noted on days 3 and 6.
We next sought to confirm the above results, and additionally
examine whether MGMT activity in tumour treated on the
dose-intense schedule might return to pretreatment levels in the
week after completing treatment, as it did with the standard
dose schedule. Nu/nu mice were inoculated with GBM43
tumour and treated exactly as described in the first experi-
ment, with the exception of the choice of time points for evalu-
ation of tumour MGMT activity. Mean MGMT activity from the
extracted brain tumours is plotted in Figure 1B, and tabulated
in Table 1. As with the first experiment, by day 6 MGMT
activity in tumour was effectively suppressed in both groups,
and rapidly returned to pretreatment levels after the comple-
tion of treatment in the schedule A group. In contrast to the
results of the first experiment, tumour MGMT activity on
schedule B remained near undetectable on day 15 and 22, and
did not show an appreciable rebound. However, by day 29,
1 week after the completion of treatment on schedule B, tumour
MGMT activity had returned to pretreatment levels. The com-
bined results from both experiments indicate that treatment
with a dose-intense temozolomide schedule results in more
prolonged suppression of MGMT activity than a standard dose
schedule, but activity quickly returns after cessation of daily
treatment.
Effect of temozolomide dosing on tumour volume
For the next set of experiments, we sought to determine whether
the more prolonged depletion of MGMT activity using the dose-
intense temozolomide schedule translated into improved tumour
control and survival. To first determine the effect of the dose-
intense temozolomide schedule on tumour volume, mice bearing
GBM43 tumours were randomly assigned 21 days after tumour
inoculation to immediate killing or treatment with no drug,
Schedule A, or schedule B (five mice per treatment group). Mice
were killed and brains harvested on day 0 (no drug) or day 22
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Figure 1 Plots of mean (s.d.) MGMT activity in orthotopic human GBM
extracted from (A) RNu rats, during and after treatment with
temozolomide on schedule A or B, on days 0 (pretreatment), 3, 6, 10,
15, and 22; and (B) nu/nu mice, during and after treatment with
temozolomide on schedule A or B, on days 0 (pretreatment), 6, 15, 22,
and 29.
Table 1 Mean MGMT activity in brain tumours extracted from RNu rats
and nu/nu mice treated with temozolomide on schedule A or B
Day
Mean MGMT activity in
brain tumour (fmol MGMT lg
 1 DNA)
Rat
No drug s.d.
0 6.40 3.27
Schedule A s.d. Schedule B s.d.
3 0.22 0.13 0.32 0.25
6 0.83 0.45 0.42 0.11
10 3.22 0.95 1.46 0.95
15 6.37 2.91 1.83 0.13
22 8.17 1.21 2.36 0.17
Mouse
No drug s.d.
0 2.19 1.47
Schedule A s.d. Schedule B s.d.
60
a 0
a 0.715 0.62
15 1.19 0.59 0
a 0
a
22 2.36 0.82 0.37 0.31
29 3.30 2.12 3.30 0.99
Abbreviation: MGMT, O
6-methylguanine-DNA methyltransferase.
aA value of ‘0’
means that there was no detectable MGMT activity in any of the samples.
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s(no drug, schedule A and B) after the start of temozolomide
treatment. Whole mount sections were made through the region of
the tumour and the section with the largest cross-sectional
diameter tumour was evaluated for tumour volume measurements.
The representative sections are shown in Figure 2 and the tumour
volume calculations are shown in Table 2. When compared with
the untreated group at day 22, both the schedule A and schedule B
tumours were smaller (Po0.01). However, no difference was
observed between the tumour volumes after treatment on
schedule A or B (P¼0.60).
Effect of temozolomide dosing on survival
To determine the effect of the dose-intense temozolomide schedule
on survival, mice inoculated with GBM43 tumour were randomly
assigned to treatment with no drug, schedule A or schedule B.
Survival for the three treatment arms is plotted in Figure 3. The
median survival was 64, 42, and 28 days for schedule A, schedule B,
and no drug, respectively. Median survival for mice treated with
schedule A or B was significantly greater than no drug (A vs no
drug, HR 4.60, Po0.0001; B vs no drug, HR 3.69, P¼0.0001).
Median survival for schedule A vs B was not significantly different
(HR 1.52, P¼0.124).
Untreated – day 0
Untreated – day 22
TMZ 5 days – day 22
TMZ 21 days – day 22
Figure 2 Photomicrographs of representative 10-micron sections showing the largest cross-sectional tumour for each mouse inoculated with human
GBM. Tumour is outlined in representative sections. Calculated tumour volumes are shown in Table 2.
Table 2 Volumes of orthotopic GBM43 tumours in nu/nu mice untreated (treatment day 0 or 22) or treated with temozolomide on schedule A or B
(treatment day 22)
Tumour volumes (mm
3)
N No treatment day 0 No treatment day 22 Schedule A day 22 Schedule B day 22
1 0.1094 23.4256 0.0026 0.0161
2 0.1228 12.1377 0.0030 0.0041
3 0.0674 10.5504 0.0019 0.0122
4 0.0367 9.1602 0.0282 0.0095
5 0.1427 3.9681 0.0055 0.0144
Average 0.0958 11.8484 0.0082 0.0112
s.d. 0.0430 7.1611 0.0112 0.0047
P-value — — Po0.01 (Schedule A vs no treatment) Po0.01 (Schedule B vs no treatment)
P¼0.60 (Schedule A vs schedule B)
Schedule A (200 mg m–2 x 5 days)
Schedule B (100 mg m–2 x 21 days)
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Figure 3 Kaplan–Meier survival curve of mice inoculated with orthotopic
human GBM and treated with temozolomide on schedule A, B, or no drug.
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sDISCUSSION
Multiple studies have now validated the clinical importance
of MGMT expression as a marker for resistance to temozolomide
in the treatment of malignant glioma (Jaeckle et al, 1998; Esteller
et al, 1999, 2000; Hegi et al, 2005; Chinot et al, 2007). Less than
40% of patients with newly diagnosed glioblastoma have inhibited
expression of MGMT because of hypermethylation of the MGMT
promoter, and 2-year survival in this group when treated with
temozolomide approached 50% on the EORTC 22981/26981 study.
The remaining patients typically have normal, or even increased
tumour MGMT expression, and 2-year survival in this group is
dismal, at o15% (Hegi et al, 2005). Although MMR and p53
mutation status also seem to have a role in the expression of
temozolomide-induced cytotoxicity, MGMT is a clearly definable
target with multiple potential methods to deplete its activity
(Liu et al, 1996; Hermisson et al, 2006). Owing to the mechanism
by which MGMT repairs O
6-methylguanine adducts and is subse-
quently degraded, the use of alternative dosing regimens is an
appealing method to enhance temzolomide mediated tumour
cytotoxicity. Although multiple preliminary lines of evidence
suggest enhanced clinical response rates with dose-intense regi-
mens, there are no published studies to date documenting the
effect of these temozolomide schedules on MGMT activity in brain
tumour. As such a study would be very difficult to perform in
humans, we attempted to measure the effects of standard and
dose-intense temozolomide schedules on human glioblastoma
MGMT activity using an orthotopic xenograft model. Furthermore,
we sought to characterise the effect of dose-intense temozolomide
dosing might have on survival. We surmised that the results of
these studies would be informative for understanding the cause
underlying the success or failure of RTOG 0525.
In this study, immunocompromised rodents were inoculated
with a human GBM line previously characterised as having an
unmethylated MGMT promoter and expressing functional MGMT
protein (Kitange et al, 2009). This particular line was taken from
an established xenograft panel serially propogated in Nu/Nu mouse
flanks, which has been characterised as maintaining the key
histopathologic features of glioblastoma including necrosis,
invasion, and nuclear pleomorphism (Sarkaria et al, 2008). After
treatment with temozolomide on either standard dose (schedule A,
200mgm
 2 for 5 days) or dose-intense (schedule B, 100mgm
 2
for 21 days) schedules, MGMT activity in tumour was maximally
depleted within 3–6 days after initiation of therapy. In the days
after completion of 5 days of treatment on the standard dose arm,
MGMT activity in tumour rapidly returned to pretreatment levels.
In contrast, tumour extracted from animals treated with the dose-
intense schedule was noted to have near complete suppression of
MGMT activity throughout treatment. However, just 1 week after
treatment with 21 days of temozolomide on the dose-intense
schedule, tumour MGMT activity had returned to pretreatment
levels. Thus, treatment with protracted temozolomide schedules
does in fact lead to persistent suppression of MGMT activity,
however, levels return rapidly to baseline with even a brief
treatment break.
Our results are in keeping with those found by Tolcher et al
(2003) in his study of MGMT levels in human PBMCs. Patients
with solid malignancy refractory to standard therapy were enrolled
onto consecutive phase I protocols evaluating two different dose-
intense temozolomide regimens, and MGMT activity in PBMCs
was measured. The first cohort received temozolomide given orally
at escalating doses from 50 to 175mgm
 2 daily for 7 days every 14
days, and PBMCs were collected at baseline, day 8, and day 15
during the first cycle of treatment. MGMT activity in PBMCs was
depleted to 28% of baseline on day 8, and recovered to 45% of
baseline by day 15. MGMT activity on day 15 was significantly
decreased compared with baseline (Po0.001), although did not
seem to be significantly different between day 8 and day 15. The
second cohort received oral temozolomide at escalating doses from
50 to 150mgm
 2 daily for 21 days every 28 days, and PBMCs were
collected at baseline, day 15, and day 22. MGMT activity in PBMCs
was significantly depleted compared with baseline on both
day 15 (63% decrease, Po0.001) and day 22 (73% decrease,
Po0.001). For minimally pretreated patients, maximum tolerated
dose was 150mgm
 2 and 100mgm
 2 for the 7-day/14-day and
21-day/28-day regimens, respectively, and dose-limiting toxicity
was secondary to thrombocytopenia and lymphopenia. Although
no comparison was made with the standard dose regimen of
200mgm
 2 for 5 days every 28 days, this study clearly showed that
dose-intense temozolomide schedules can effectively deplete
MGMT activity in PBMCs.
Two previously reported studies have attempted to examine the
effect of dose-intense temozolomide regimens on MGMT activity
in tumour. In the first, Gander et al (1999) treated 24 patients
(22 with metastatic melanoma, 2 with recurrent glioma) on a
prospective trial evaluating escalating doses of temozolomide from
300 to 700mgm
 2 divided over 2 days. Patients were also treated
with fotemustine 100mgm
 2 on day 2, given 4h after the
temozolomide dose. In a subset of six patients with accessible
metastatic melanoma deposits, MGMT activity was assessed in
PBMCs and tumour at baseline and 4h after the initiation of
treatment. After treatment with temozolomide, mean MGMT
activity in tumour was depleted to 56% of pretreatment levels. It
is noteworthy that in three of the six patients there was
discordance between changes in MGMT activity in PBMCs and
tumour – two patients had an increase in PBMC MGMT activity
and a decrease in tumour levels, and one patient had a decrease in
PBMC MGMT activity and an increase in tumour levels. In the
second study, Spiro et al (2001) treated 22 patients with metastatic
solid tumours on a phase I trial with either (1) a bolus dose of
temozolomide 200mgm
 2 followed by escalating doses starting
at 50mgm
 2 given every 12h for 5 days every 28 days, or
(2) temozolomide 200mgm
 2 given daily for 5 days every 28 days.
MGMT activity was assessed in PBMCs at regular intervals in all
patients, and in core biopsies of liver metastases at baseline and 2h
after the last dose of temozolomide in 15 patients. At 24h, patients
assigned to treatment with twice daily temozolomide had lower
mean levels of MGMT activity in PBMCs compared with the once
daily group (o10 vs 50% of baseline, Po0.0001). Baseline tumour
MGMT activity varied significantly between patients, as well as
between sections of a tumour biopsy in the same patient. After
treatment, mean depletion in MGMT activity varied from 0 to 84%
in patients treated with a cumulative dose of 1000mgm
 2, and
varied from 20 to 78% in those who received 1010mgm
 2. Two
patients received a cumulative dose of 1100mgm
 2, one of which
showed 99.5% inactivation and the other showed no decrease at all.
No clear correlation was noted between depletion of MGMT
activity in PBMCs and tumour, nor was there a correlation between
depletion of tumour MGMT activity and response rate. Although
neither study used the more commonly used 7-day/14-day or
21-day/28-day regimens, nor was brain tumour specifically
evaluated, both studies suggest that dose-intense temozolomide
schedules can deplete MGMT activity in tumour. Common
between the two studies was discordance in several patients
between changes in MGMT activity in PBMCs and tumour.
Recently, Kitange et al (2009) attempted to further characterise
changes in MGMT expression in several of the glioblastoma lines
from the Mayo xenograft panel, which included assessment of the
GBM43 line. After treatment of GBM43 cells in short-term culture
with a single dose of 100mM temozolomide, they found a two-fold
induction in MGMT expression 48h after treatment, as quantified
by both western blot and RT–PCR. The influence of temozolomide
treatment on MGMT activity in tumour was then evaluated in mice
with established flank GBM43 tumours. Mice were treated with
temozolomide at 50mgkg
 1 daily for 5 days, and at serial time
points (days 0, 1, and 7 after treatment), animals were killed and
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sMGMT activity was assessed in flank tumour. Compared with
MGMT activity on day 0, relative activity by day 7 had increased
13-fold. The results of this analysis are not directly comparable to
our own, however, as no assessment was made of intracranial
tumour activity, and all measurements of MGMT expression and
activity were made after treatment with temozolomide. Nonetheless,
these results indicate that treatment with temozolomide leads to
increased MGMT expression in the GBM43 line, at least in the week
after treatment. In this study, MGMT activity in intracranial tumour
samples taken 1–2 weeks after treatment was not clearly higher than
pretreatment levels, although the trend is suggestive.
After showing that dose-intense temozolomide results in more
prolonged depletion of intracranial tumour MGMT activity
compared with a standard dose schedule, we next sought to
determine whether treatment with the dose-intense schedule might
improve tumour response, as defined by assessment of pre- and
post-treatment tumour volumes and survival. In both sets of
experiments, mice with orthotopically implanted GBM43 were
randomly assigned to treatment with no drug, temozolomide
200mgm
 2 daily for 5 days, or temozolomide 100mgm
 2 daily for
21 days. Tumour volumes at the completion of therapy for mice
treated with either temozolomide schedule were significantly
smaller compared with no treatment, however, there was no
appreciable difference in final tumour volume between the two
treatment schedules. Similarly, median survival for mice treated
with either temozolomide schedule was significantly improved
compared with no treatment. Again, however, there was no
statistically significant difference in median survival between the
two treatment schedules. Kitange et al (2009) also evaluated
survival in mice with orthotopically implanted GBM43 treated with
temozolomide using (1) 50mgkg
 1 daily for 5 days per week over
2 weeks (500mgkg
 1 total dose), (2) 120mgkg
 1 once a week for
2 weeks (240mgkg
 1 total dose), and (3) 120mgkg
 1 daily for 5 days
(600mgkg
 1 total dose). Relative to treatment with vehicle alone,
survival was 1.3 times control in mice treated with either the daily
50mgkg
 1 or twice-weekly 120mgkg
 1 schedules, and 2.0 times
c o n t r o li nm i c et r e a t e dw i t ht h ed a i l y1 2 0m gk g
 1 schedule. The daily
120mgkg
 1 schedule resulted in significantly improved survival
compared with the other two schedules (Po0.01). The investigators
conclude that the more protracted regimens resulted in inferior
tumour control as a result of the induction in MGMT expression after
treatment with temozolomide. Whether this rationale entirely
explains the lack of a survival benefit to treatment with dose-dense
temozolomide in this study is not clear. In fact, in the current
analysis, the dose-dense regimen effectively suppressed MGMT
activity in tumour, and thus any induction in expression of protein
expression was presumably countered by inhibition of enzyme
activity. However, although MGMT activity was reliably suppressed to
levels below 20–30% of baseline, iti sp o s s i b l et h a te v e nl i m i t e d
MGMT activity may be sufficient to repair the O
6-methylguanine
lesions generated by temozolomide. Thus, complete inhibition may
be what is necessary to show an appreciable improvement in tumour
control, and whether this is achievable with modifications in
temozolomide scheduling alone remains to be determined.
In the recently completed RTOG 0525 phase III trial, patients
with newly diagnosed glioblastoma underwent a maximal safe
resection, followed by 6 weeks of temozolomide and radiation as
delivered by the EORTC 22981/26981 regimen. Patients were
randomised to treatment with 12 cycles of adjuvant temozolomide
delivered using either a standard (200mgm
 2 daily for 5 days
every 28 days) or dose-intense (100mgm
 2 daily for 21 days every
28 days) schedule. The design for the trial was based in large part
on the work by Tolcher et al (2003), showing enhanced depletion
of MGMT activity in the PBMCs of patients subjected to two
different dose-intense temozolomide regimens.
Another unstated assumption of the RTOG 0525 trial is that
modification of the final adjuvant temozolomide portion of
treatment might be sufficient to affect overall survival. With the
implementation of the EORTC 22981/26981 regimen as the new
standard of care, temozolomide was simultaneously introduced
concurrently with radiotherapy, and as part of a planned 6–12
cycles of continued adjuvant temozolomide using a standard
dosing schedule. One recent publication has attempted to address
the relative importance of the concurrent and adjuvant temozo-
lomide portions of the EORTC 22981/26981 regimen. Sher et al
(2008) retrospectively analysed the outcomes of 43 patients with
glioblastoma treated at a single institution with surgical resection
and involved field radiotherapy. In total, 21 patients received
adjuvant temozolomide alone after radiotherapy, and 22 received
temozolomide concurrent with radiotherapy, followed by addi-
tional adjuvant temozolomide. At a median follow-up of 33.7
months, the hazard ratio for survival trended towards significance
in favour of treatment with concurrent and adjuvant temozolo-
mide over adjuvant temozolomide alone (HR¼0.51, P¼0.08).
This study is the first to methodically assess changes in
intracranial glioblastoma MGMT based on modifications in
temozolomide dosing. Using the clinically relevant schedules
from the RTOG 0525 trial, we determined that a dose-intense
temozolomide schedule is more effective than a standard dose
schedule at depleting MGMT activity in human glioblastoma using
an orthotopic xenograft model. In spite of the improved MGMT
activity depletion, there was no apparent survival benefit to dose-
intense temozolomide when the same model was challenged with
the two schedules, in this single treatment cycle model of
glioblastoma. Regardless of the absence of a survival benefit, the
tumour MGMT activity results lend validity to the basic premise of
the RTOG 0525 trial and other ongoing trials using dose-intense
temozolomide regimens in the treatment of newly diagnosed or
refractory glioblastoma. Results from the recently completed
RTOG 0525 trial are anxiously awaited.
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